Plus Therapeutics, Inc. (Nasdaq: PSTV) issued a statement July 14, 2026, noting a recent update to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Central Nervous System Cancers, which the company says reinforces the clinical relevance of its CNSide cerebrospinal fluid (CSF) assay platform in leptomeningeal metastases (LM) monitoring.

The updated NCCN guidelines state that CSF analysis remains a standard component of LM diagnosis and that, in patients receiving intrathecal therapy, CSF cytology is typically re-evaluated every four to eight weeks alongside MRI and clinical evaluation.

CNSide is a CSF assay platform developed by CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics. Data from the company's FORESEE study indicated that CNSide more than doubled the sensitivity of tumor detection compared with conventional cytology in matched CSF samples from LM patients.

"A quantitative assay such as CNSide Tumor Cell Enumeration can complement standard cytology by detecting disease more sensitively and by enabling longitudinal monitoring of tumor burden over time," said Michael Youssef, M.D., neuro-oncologist at Houston Methodist.

The company previously reported health economics data suggesting CNSide use may reduce LM-related healthcare costs by approximately 40%. Leptomeningeal metastases are estimated to occur in 5% to 10% of cancer patients.

CNSide has received Medicare enrollment approval, CAP accreditation, and payer coverage agreements with Blue Shield of California and Elevance Health. Following the Elevance agreement, the company reported total contracted coverage of approximately 126 million covered lives in the United States. The company has stated a 2026 objective of 150 million covered lives and 1,250 total CNSide tests performed.

Separately, Plus Therapeutics announced it will change its corporate name to Cerenome, Inc. and begin trading on Nasdaq under the ticker symbol CNSY effective August 3, 2026. Until that date, the company will continue to trade as PSTV.